NanoGhost - Harnessing the homing nature of stem cells in a drug targeting platform

NanoGhost is a biotech company that develops a highly selective first-in-class platform for drug targeting (Nano-Ghosts) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.

Nano-Ghosts (NGs) are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intra cellular niches, with versatile loading capacity and broad therapeutic applicability.

In various preclinical cancer models, NGs demonstrated targeting capability and high selectivity. NGs are retained at the tumor niche while cleared within few hours from normal tissues. This system crosses the BBB and desmoplastic barriers, as demonstrated in glioblastoma and pancreatic cancer models, respectively. In addition, NGs can be loaded with various drug types at a wide payload size range and retain MSC’s allo-tolerability allowing their use as an ‘Off the shelf’ product.

Nano-Ghost is aiming at targeting potent drugs (such as SN-38, a topoisomerase inhibitor, and IL-12, an immune activating drug) that are limited by high toxicity or are currently delivered by intra tumoral injection to cancers with high unmet need. Preclinical development is currently underway.